Ovarian function and pregnancy outcome in pony mares following immunocontraception with native and recombinant porcine zona pellucida vaccines

Joone, Christopher; Bertschinger, H.J.; Gupta, Satish Kumar; Fosgate, Geoffrey T.; Arukha, Ananta Prasad; Minhas, Vidisha; Dieterman, E.; Schulman, Martin L.

doi:10.1111/evj.12557

Cited by 21 publications

(50 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specimens were obtained from two previously-reported controlled studies in the mare that described the ovarian effects and reversibility of native pZP, recombinant porcine ZP3 and ZP4 [8] and GnRH vaccines [14,23]. Briefly, native pZP (Trumpeter Farms and Veterinary Services, Winters, California, USA) was prepared according to standard methods [4].…”

Section: Experimental Designmentioning

confidence: 99%

“…For the ZP vaccine study, mares were stratified according to age and randomly assigned to one of three study groups: pZP, reZP and saline-treated controls (n = 7 per group) [8]. All treatments For the GnRH study, mares were stratified according to age and randomly assigned to either GnRH vaccine (n = 9) or saline-treated control (n = 3) groups [14,23].…”

Section: Experimental Designmentioning

confidence: 99%

“…The ovarian effects of pZP immunocontraception in the mare have been assessed clinically (transrectal palpation and ultrasonography), histologically (ovarian histology) and endocrinologically (measurements of ovarian steroids or their metabolites) [4][5][6][7][8]. Initial reports observed no ovarian effects following short-term pZP treatment [4].…”

Section: Introductionmentioning

confidence: 99%

“…Longer intervals (up to 7 years) of anti-pZP immunization resulted in decreased ovarian oestrogen production and ovulation rates [5,9]. More recently, ovarian inactivity was detected in > 86% of mares within four months of treatment with both the conventional pZP vaccine [8] and a single-dose formulation of pZP [7]. The latter two studies highlighted a need for further study of the mechanism of action of ZP-based vaccines in the mare.…”

Section: Introductionmentioning

confidence: 99%

“…This study aimed to investigate AMH in mares following their active immunisation against one of GnRH, native pZP or a combination of recombinant pZP3 and pZP4 (reZP; [22]) vaccines. Measured AMH was then compared to previously-published clinical variables, including mare age, serum progesterone concentrations, mean ovarian volumes and AFC or the presence of follicles > 20 mm in diameter [8,14,23].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Serum anti-Müllerian hormone dynamics in mares following immunocontraception with anti-zona pellucida or -GnRH vaccines

et al. 2018

View full text Add to dashboard Cite

Circulating anti-Müllerian hormone concentration (AMH) is positively correlated to the number of small growing follicles in the mare and may reflect ovarian function. Dynamics of AMH during immunocontraception have not previously been investigated. This study aimed to compare serum AMH in mares following treatment with native porcine zona pellucida (pZP), recombinant pZP3 and pZP4 (reZP) or gonadotrophin releasing hormone (GnRH) vaccines, and saline-treated controls. Stored sera collected during two previous studies examining ovarian activity in mares during zona pellucida (ZP) or GnRH immunocontraception were analysed for serum AMH. Data were compared among treatment groups using mixed-effects linear regression and one-way ANOVA with post hoc testing. Correlations between AMH and previously reported clinical variables were estimated using Spearman's rho. Mares immunized against GnRH showed variable but detectable AMH throughout successive breeding and non-breeding seasons that were not significantly different to unvaccinated control mares. Mares treated with pZP demonstrated marked, reversible suppression of AMH. Mares immunized using reZP showed an intermediate effect. In the ZP study, AMH was positively correlated to serum progesterone concentrations, mean ovarian volumes and antral follicle counts, whereas no correlations between AMH and serum progesterone concentrations, mean ovarian volumes, or the presence of one or more follicles ≥20 mm in diameter were detected in the GnRH study. In conclusion, marked suppression of AMH during pZP immunocontraception, but not during GnRH immunocontraception, suggested enhanced suppression of ovarian follicular development and, or follicular function during pZP immunocontraception. Serum AMH concentrations may provide a novel tool for the assessment of ovarian function during ZP-based immunocontraception.

show abstract